IMVIONIX Acquires U.S. and Canadian Rights to BEOVU® (brolucizumab-dbll), Marking the Company's Official Launch

Acquisition of FDA-Approved Retinal Therapy Signals IMVIONIX's Entry as a Commercial-Stage Ophthalmology Company

PEACHTREE CORNERS, Ga., Nov. 10, 2026 /PRNewswire/ -- IMVIONIX Inc., a privately held biotechnology company dedicated to advancing the delivery of retinal therapies, today announced that it has acquired exclusive commercial rights to BEOVU^® (brolucizumab-dbll) in the United States and Canada from Novartis. This acquisition marks the official commercial launch of IMVIONIX and represents the company's first strategic transaction in its mission to improve vision by advancing the reach of retinal therapies where unmet needs for patients and physicians persist.

"We founded IMVIONIX because we believe there are proven retinal therapies where physicians and patients can further benefit from the focus and reach of a dedicated retina company," said Rick Eiswirth, Founder and Chief Executive Officer of IMVIONIX. "Building on the strong foundation already established for BEOVU^®, this acquisition exemplifies the type of opportunity IMVIONIX was built to pursue." IMVIONIX believes that an organization with deep relationships in the retina community is best positioned to expand the reach of such therapies and bring them to the physicians and patients who may potentially benefit most. "We are excited to bring our focused commercial expertise to bear on behalf of the retina community," Eiswirth continued.

BEOVU^® is approved in both the United States and Canada for the treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME), two leading causes of irreversible vision loss. Under the terms of the agreement, IMVIONIX will become the marketing authorization holder for BEOVU^® in the United States and Canada. Financial terms of the transaction were not disclosed.

IMVIONIX was founded in 2025 by the former executive management team of Alimera Sciences, Inc. — Rick Eiswirth, Jason Werner, Todd Wood, and Elliot Maltz — in collaboration with Caligan Partners LP and Velan Capital. The founding team brings a combined 60 years of expertise in ophthalmology.

"The acquisition of BEOVU^® marks an important first step in building IMVIONIX into a company that focuses on serving retina specialists and their patients," Eiswirth added. "BEOVU^® has proven efficacy in two significant retinal conditions, and we believe it is well positioned to deliver additional meaningful value to the retina community. This acquisition reflects our core mandate — identifying therapies that align with our retina focused investment and commercialization platform. Our team has a proven track record of bringing ophthalmic therapies to market and we are well capitalized to execute on our mission."

About IMVIONIX
IMVIONIX is a privately held ophthalmology biotechnology company focused on advancing the delivery of retinal therapies. Founded in 2025 in collaboration with Caligan Partners LP and Velan Capital, IMVIONIX identifies, develops, and commercializes promising treatments that retina patients and physicians may need but cannot reach. The acquisition of U.S. and Canadian rights to BEOVU® was supported by Caligan Partners LP and its investors. The company was founded by Rick Eiswirth, Jason Werner, Todd Wood, and Elliot Maltz who bring deep experience building ophthalmology brands and a proven track record in retinal disease. Together they successfully commercialized retinal therapies targeting unmet needs and helped improve patient outcomes. For more information, please visit www.imvionix.com.

About BEOVU^® (brolucizumab-dbll)
BEOVU^® (brolucizumab-dbll) is a humanized single-chain antibody fragment (scFv) VEGF inhibitor administered by intravitreal injection. BEOVU® is indicated in both the United States and Canada for the treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME), two leading causes of irreversible vision loss.

Important safety information for BEOVU® includes risks of endophthalmitis, retinal detachment, retinal vasculitis, and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, increases in intraocular pressure, and potential risk of arterial thromboembolic events. Patients should be instructed to report any symptoms suggestive of endophthalmitis, retinal detachment, or any change in vision without delay.

Please see full Prescribing Information for BEOVU^® at www.beovu.com.

BEOVU® is a registered trademark of Novartis AG and is used under license.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Forward-looking statements are based on management's current expectations and are subject to change. IMVIONIX undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date hereof, except as required by law.

SOURCE IMVIONIX